Cellectis (NASDAQ:CLLS) Share Price Passes Above 50-Day Moving Average – Should You Sell?

Cellectis S.A. (NASDAQ:CLLS)’s stock price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $3.70 and traded as high as $3.98. Cellectis shares last traded at $3.85, with a volume of 13,554 shares.

Analyst Ratings Changes

A number of research firms recently issued reports on CLLS. Jefferies Financial Group began coverage on Cellectis in a report on Tuesday, February 17th. They set a “buy” rating and a $7.00 target price on the stock. Citizens Jmp reissued a “market outperform” rating and issued a $8.00 price target on shares of Cellectis in a research note on Tuesday, April 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.75.

Cellectis Stock Up 0.8%

The business has a 50 day moving average of $3.70 and a 200 day moving average of $4.02. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.52 and a quick ratio of 1.52. The firm has a market capitalization of $367.24 million, a price-to-earnings ratio of -5.46 and a beta of 2.94.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.08. The company had revenue of $7.55 million for the quarter, compared to analysts’ expectations of $11.04 million. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.

Institutional Investors Weigh In On Cellectis

Hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC bought a new position in shares of Cellectis in the 4th quarter valued at $34,000. Lido Advisors LLC bought a new stake in Cellectis during the 1st quarter worth $32,000. Millennium Management LLC grew its position in Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 22,080 shares during the last quarter. Delaney Dennis R bought a new stake in Cellectis during the 3rd quarter worth $68,000. Finally, B Group Inc. grew its position in Cellectis by 0.8% during the 3rd quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock worth $9,352,000 after acquiring an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.